Search

Your search keyword '"Manoukian, Siranoush"' showing total 1,289 results

Search Constraints

Start Over You searched for: Author "Manoukian, Siranoush" Remove constraint Author: "Manoukian, Siranoush"
1,289 results on '"Manoukian, Siranoush"'

Search Results

1. A Likelihood Ratio Approach for Utilizing Case‐Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2

2. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

4. Rare germline copy number variants (CNVs) and breast cancer risk

5. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.

6. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

7. Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities

8. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

9. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study

10. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.

11. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

12. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison

13. The impact of coding germline variants on contralateral breast cancer risk and survival

14. Two truncating variants in FANCC and breast cancer risk.

15. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

16. Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.

17. The BRCA2 c.68‐7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

19. Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care

20. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.

21. Correlation between oncological family history and clinical outcome in a large monocentric cohort of pediatric patients with rhabdomyosarcoma

23. Atypical cancer risk profile in carriers of Italian founder BRCA1 variant p.His1673del: Implications for classification and clinical management.

24. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

25. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

26. Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer

27. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).

28. Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry.

29. Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry

30. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.

31. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

32. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

33. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

34. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility

35. Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk.

36. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

37. Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

38. Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

39. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

40. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.

41. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

42. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

43. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.

45. A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy

47. Genome-wide association study of germline variants and breast cancer-specific mortality

48. 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

49. Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)

50. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.

Catalog

Books, media, physical & digital resources